BODIPY-Tagged β-Lactams as Selective Quenched Activity-Based Probes to Target Human Neutrophil Elastase

This study reports the development of highly selective, BODIPY-tagged, quenched activity-based probes utilizing a β-lactam warhead that effectively target and visualize Human Neutrophil Elastase in both cell lysates and live human neutrophils, offering new potential for investigating the enzyme's role in cancer.

The Gist

The Big Picture: Finding a Hidden Culprit

Imagine your body is a bustling city. Usually, the police (your immune system) keep things in order. But sometimes, a specific police officer gets a little too aggressive and starts causing trouble in the wrong neighborhoods. This "officer" is an enzyme called Human Neutrophil Elastase (HNE).

While HNE is good at fighting infections, when it gets loose in the wrong places (like in the lungs of cystic fibrosis patients or inside a tumor), it acts like a vandal, tearing down healthy tissue and helping cancer grow.

The Problem: Scientists know HNE is a troublemaker, but they can't easily find it or track it. It's like trying to find a specific person in a crowded stadium wearing a plain grey suit. If you shine a flashlight on the whole crowd, you just see a blinding white glare (background noise), and you can't spot the specific person you are looking for.

The Solution: The "Magic Flashlight"

The researchers in this paper invented a new kind of "smart flashlight" called a Quenched Activity-Based Probe (qABP).

Think of it this way:

1. The Bait: They built a tiny trap shaped exactly like the handcuffs HNE likes to wear. This trap is made of a chemical ring called a $\beta$-lactam (the same family as penicillin).
2. The Light: Attached to the trap is a bright, glowing light bulb (a BODIPY fluorophore).
3. The Cover-Up: But here's the trick: the light bulb is covered by a heavy, black blanket (a quencher). So, when the probe is floating around in your blood or cells, it is completely dark. It doesn't glow at all. This solves the "blinding glare" problem.

How It Works: The "Snap-Open" Mechanism

The magic happens when the probe meets its target, HNE.

• The Encounter: HNE sees the trap (the $\beta$-lactam ring) and thinks, "Hey, that's my handcuff!" It grabs onto it.
• The Snap: HNE tries to break the ring to use it. When it snaps the ring, the "black blanket" (the quencher) falls off.
• The Flash: Suddenly, the light bulb is exposed and starts glowing brightly!

Because the light only turns on when HNE actually grabs the probe, scientists can now see exactly where HNE is hiding. If there is no HNE, the probe stays dark. If there is HNE, it lights up like a firefly.

Two Types of Traps

The scientists built two different versions of this trap, which they called Type I and Type II.

• Type I: This version works, but it's a bit slow. It's like a door that opens, but the hinges are a little rusty. The "blanket" falls off, but it takes a while, and the light doesn't get as bright as quickly.
• Type II: This is the upgraded model. The scientists redesigned the trap so that when HNE grabs it, the "blanket" flies off instantly. It's like a spring-loaded door that snaps open immediately. The light turns on faster and brighter.

The Results: Catching the Culprit in the Act

The researchers tested their new "Type II" probes in the lab and found they were amazing:

1. Super Selective: They only lit up when they met HNE. They ignored other similar enzymes (like a bouncer who only lets in the VIP and turns away everyone else).
2. Works in the Real World: They tested the probes on actual human cells and even on human white blood cells (neutrophils). The probes successfully entered the cells, found the HNE inside, and lit up.
3. No Washing Needed: Because the probe is dark until it hits the target, scientists didn't have to wash away the extra probes to see the signal. This makes it perfect for watching what happens in real-time, like filming a movie instead of looking at a still photo.

Why This Matters

This new tool is like giving scientists a pair of night-vision goggles specifically tuned to see HNE.

• For Cancer: It helps researchers see how HNE helps tumors grow and spread, which could lead to better cancer drugs.
• For Lung Diseases: It helps track HNE in diseases like cystic fibrosis, allowing doctors to see if their treatments are actually stopping the enzyme.

In short, the team created a "smart, self-illuminating trap" that allows us to finally see and study a hidden biological troublemaker, opening the door to better treatments for some of the world's toughest diseases.

Technical Summary

1. Problem Statement

Human Neutrophil Elastase (HNE) is a serine hydrolase implicated in inflammatory diseases and increasingly recognized for its role in the tumor microenvironment, where it promotes tumor growth and metastasis. However, the specific dynamics and localization of HNE in complex biological systems remain poorly understood due to a lack of selective chemical tools.

• Limitations of Current Tools: Traditional Activity-Based Probes (ABPs) often suffer from high background fluorescence because the fluorophore is present even before the probe reacts with the enzyme. This necessitates extensive washing steps, making them unsuitable for real-time imaging or applications where background noise cannot be easily removed.
• Gap in Technology: While quenched ABPs (qABPs) exist for cysteine proteases, their development for serine hydrolases like HNE is limited. Existing HNE probes often rely on complex peptide linkers or release the fluorophore into the solution (preventing gel-based analysis), or they lack the necessary selectivity and cell permeability.

2. Methodology

The authors developed a synthetic strategy to create two distinct classes of quenched Activity-Based Probes (qABPs) featuring a monobactam (β-lactam) ring as the reactive warhead and BODIPY-FL as the fluorophore.

• Design Strategy:

  • Warhead: A monobactam scaffold was chosen for its ability to irreversibly inhibit serine hydrolases.
  • Quenching Mechanism: A fluorescence quencher (dinitrobenzene or cAB40) is attached to the warhead. Upon enzymatic cleavage, the quencher is released, separating it from the fluorophore and restoring fluorescence ("turn-on" mechanism).
  • Two Probe Types:
    • Type I: The quencher is attached via a linker and released as an acid/analogous moiety.
    • Type II: The quencher is attached directly to the four-membered ring via a phenol leaving group. This design aims to increase the $pK_a$ of ring opening, enhancing reactivity and ensuring the quencher is released as a phenol.

• Synthesis:

  • Type I Synthesis: Started with azetidinone 1, underwent a Barbier-type reaction to introduce an alkyne, followed by hydroxymethylation. The quencher was coupled to the hydroxyl group, deprotected, and finally conjugated to a BODIPY-azide via "click" chemistry (CuAAC).
  • Type II Synthesis: Involved substituting an acetal group on azetidinone 1 with a phenol-quencher intermediate, followed by urea formation on the lactam ring to introduce the alkyne. Final conjugation with BODIPY-azide yielded the probes.

• Evaluation:

  • Photophysical Properties: Stability in PBS and pH-dependent activation were tested via UV-Vis and fluorescence spectroscopy.
  • Enzymatic Assays: Kinetics were measured using Porcine Pancreatic Elastase (PPE) as a model, followed by pure HNE.
  • Selectivity: IC50 values were determined against HNE and a panel of related serine proteases (Chymotrypsin, Thrombin, Kallikrein, Urokinase).
  • Biological Validation: Probes were tested in cell lysates (HEK293, A431, U937, human neutrophils) via SDS-PAGE gel imaging.
  • Cellular Internalization: Live-cell uptake was assessed in U937 cells (flow cytometry) and human neutrophils (high-content imaging).

3. Key Contributions

• Novel Scaffold: First report of a monobactam ring used as a warhead in a qABP for serine hydrolases.
• Dual Mechanism Design: Introduction of two distinct activation mechanisms (Type I vs. Type II) to optimize the release of the quencher.
• High Selectivity: Development of probes that distinguish HNE from highly homologous serine proteases without the need for complex peptidyl linkers.
• Cell-Permeable qABPs: Successful creation of probes that can penetrate living cells and target endogenous HNE, overcoming the limitations of previous non-permeable or high-background probes.

4. Results

• Photophysical Performance:

  • Quenching Efficiency: All probes showed low baseline fluorescence (Quantum Yield $\Phi_F$ < 26% in PBS), indicating effective quenching.
  • Activation: Upon activation (simulated by NaOH or enzyme), $\Phi_F$ increased significantly (up to 92%).
  • Kinetics: Type II probes demonstrated superior performance. They released the quencher faster and more efficiently than Type I. In enzyme assays, Type II probes showed a 6-fold fluorescence increase within 3 hours, whereas Type I required 19 hours for a 4-fold increase.

• Inhibitory Activity and Selectivity:

  • IC50 Values: All probes exhibited strong inhibition of HNE with IC50 values < 0.5 µM (e.g., Probe 22: 0.19 µM).
  • Selectivity: Type II probes showed excellent selectivity, with IC50 values > 10 µM against Chymotrypsin, Thrombin, Kallikrein, Urokinase, and PPE. This confirms high specificity for HNE.

• Biological Validation:

  • Gel-Based Assays: Type II probes (specifically Probe 22) successfully labeled HNE in complex proteomes (HEK293 and A431 lysates spiked with HNE) with minimal background.
  • Endogenous Targeting: Probe 22 successfully detected endogenous HNE in U937 cells (monocytic line) and human neutrophils without requiring overexpression.
  • Competitive Assay: Pre-incubation with the known HNE inhibitor ONO-6818 abolished the signal, confirming the probes bind to the active site.

• Cellular Internalization:

  • Flow Cytometry: U937 cells treated with Probe 22 showed a marked increase in fluorescence compared to controls.
  • Live Imaging: Confocal microscopy of human neutrophils confirmed cytoplasmic accumulation and activation of Probe 22 within 2 hours.

5. Significance

This study provides a robust chemical toolset for investigating the elusive role of HNE in the tumor microenvironment and cancer progression.

• Overcoming Imaging Barriers: The "turn-on" mechanism eliminates background noise, enabling real-time imaging and reducing the need for washing steps, which is critical for in vivo or live-cell applications.
• Mechanistic Insight: The success of the monobactam warhead suggests a new avenue for designing inhibitors and probes for serine hydrolases beyond traditional peptide-based approaches.
• Future Applications: These probes (particularly Probe 22) can now be used to map HNE activity in complex tissues, validate HNE as a therapeutic target, and potentially screen for novel HNE inhibitors in drug discovery pipelines.

In conclusion, the authors successfully synthesized and validated a new generation of highly selective, cell-permeable, quenched activity-based probes that effectively target Human Neutrophil Elastase, offering a significant advancement in chemical proteomics for serine hydrolases.